Capsule summary: This emulation of a hypothetical trial shows that, in comparison to omalizumab and mepolizumab, dupilumab is associated with greater reductions in asthma exacerbations in patients with eosinophil counts of ≥150 cells/microliter and IgE levels of 30–700 kU/L.
All Keywords
【저자키워드】 Asthma, monoclonal antibodies, comparative effectiveness, Dupilumab, omalizumab, Target trial emulation, allergic, mepolizumab, Eosinophilic,
【저자키워드】 Asthma, monoclonal antibodies, comparative effectiveness, Dupilumab, omalizumab, Target trial emulation, allergic, mepolizumab, Eosinophilic,